Ann: PAA & ONJCRI to Continue MPL Pre-clinical Investigations, page-37

With so many irons in the fire it can be easy to overlook the important work which is being done behind the scenes.
Even though the announcement was made in January, here is a reminder of what is occurring at ONJ Cancer Research Institute from their website:

https://www.onjcri.org.au/latest-news/staff/monepantel-preclinical-investigations-to-continue-with-pharmaust/

"Using state-of-the-art techniques, the team will now examine these genes in greater detail and match changes in their activity with changes in associated protein signalling pathways. These experiments are aimed at determining what happens within the cancer cell once MPL interacts with its primary molecular targets, and then exerts its downstream and definitive anti-cancer activity. Establishing MPL’s mechanism of action in this detail will enable differentiation of MPL’s effects upon cancer cells compared to other anti-cancer drugs, thus assisting with regulatory submissions and marketing moving through Phase III and IV trials."

Any update on progress would be most welcome by shareholders.